24 March 2021
Oxford BioDynamics Plc
Results of Annual General Meeting
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, announces that all resolutions at the Company's Annual General Meeting, held earlier today, were duly passed.
-ENDS-
For further details please contact:
| Oxford BioDynamics Plc | Tel: +44 (0)1865 518910 |
| Jon Burrows, CEO Paul Stockdale, CFO |
|
|
|
|
| Shore Capital - Nominated Adviser and Broker | Tel: +44 (0)20 7408 4090 |
| Advisory: Edward Mansfield / John More Broking: Fiona Conroy |
|
|
|
|
| Instinctif Partners | Tel: +44 (0)20 7457 2020 |
| Melanie Toyne-Sewell / Agnes Stephens / Katie Duffell / Nathan Billis | OxfordBioDynamics@instinctif.com |
NOTES TO EDITORS:
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
OBD launched the EpiSwitch® CST, a highly accurate prognostic test that predicts personalized risk of severe illness from COVID-19, to the US market in March 2021. The next test to launch will be a predictive immune response profile for Immuno-oncology checkpoint inhibitor treatments.
The Company has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The proprietary technology portfolio includes biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
